Clinical Research Directory

Inclusion Criteria: * Age≥18 years old and ≤80 years old. * Complete R0 resection for pancreatic cancer with no evidence of malignant ascites, peritoneal metastases or distant metastases. * Histology confirmed pancreatic adenocarcinoma. * Eligible histologic variants include adenocarcinoma or variants to include mucinous adenocarcinoma or adenosquamous carcinoma. * No metastases are found in preoperative examination. * No prior chemotherapy or radiotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy of greater than 90 days, as judged by the investigator. * Routine blood test: absolute neutrophil count\>1500/mm3, platelet\>100000/mm3. * Normal liver function: serum total bilirubin≤2.0mg/dl, aminotransferase (ALT) and aspertate aminotransferase (AST) \<2.5 times of the upper limit of normal value. * Normal kidney function: serum creatinine\<1.5 times of the upper limit of normal value or creatinine clearance rate\>45ml/min. * The pancreatic cancer organoid were cultured successfully. * No severe comorbidities. Exclusion Criteria: * Patients with poor condition can not tolerate chemotherapy and targeted therapy. * Impaired organ functions: heart failure (New York Heart Association III-IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure. * Patients diagnosed with other cancer within 5 years. * Patients who are pregnant or breastfeeding. * Patients enrolled in other clinical trials or incompliant of regular follow up. * Patients who did not provide an informed consent.